TERT and cancer: Besides, our data indicate that RT domain of TERT may act not only as an immunogen but also as a source of RNA and RNA/DNA triggering production of type I IFNs, i.e., provide in-built adjuvant(s) triggering the desired type of innate immune response against cancer cells.